• December 2004: Napa Jenomics Corporation established in California, USA
  • July 2005: Napa Jenonics K.K. established in Tokyo, Japan as a subsidiary of Napa Jenomics Corporation
  • February 2009 Company started to focus nucleic acid drug discovery and development effort
  • July 2011: Napa Jenomics Corporation changes name to NapaJen Pharma, Inc,
  • January 2014: Closed Series A financing
  • December 2016: Closed Series B financing
  • January 2017: Advanced NJA-730 into development stage
  • January 2018: Napa Jenomics Co., Ltd. changes name to NapaJen Pharma Co., Ltd.
  • September 2018: Phase 1 clinical trial of NJA-730 launched in Australia
  • January 2019: Closed Series C financing